People In Brief
This article was originally published in The Gray Sheet
Executive Summary
St. Jude Medical brings John Brown on board: Stryker's former CEO John Brown joins St. Jude's board of directors. Brown, who remains on Stryker's board, served as CEO of the orthopedic firm for 28 years before retiring earlier this year. During Brown's reign, Stryker grew from a family-owned company with $22.7 mil. in annual sales in 1978 to a Fortune 500 company with $4.3 bil. in annual sales in 2004. St. Jude's expanded defibrillator product line propelled ICD sales 92% during the quarter to $244 mil. (1"The Gray Sheet" July 25, 2005, p. 18)...
You may also be interested in...
Med-Tech Earnings In Brief
Zimmer on gainsharing deal: Orthopedic firm concludes contractual agreements, sets June 1 as a starting point in gainsharing deal with HCA, the largest for-profit hospital group in the U.S. "The opportunity to chase several millions of dollars of new business with a less-crowded field of competitors is always welcome, provided real compliance is delivered," Zimmer CEO Ray Elliott said during a second quarter conference call. Zimmer believes there is little downside to the arrangement, but the firm is monitoring the situation, and thus far "we do not have any proof that this construct will move material amounts of business. Failure to do so must result in a return to higher prices and/or less services." Under the deal, HCA will only purchase reconstructive implants from Stryker, Zimmer and J&J/DePuy (1"The Gray Sheet" April 25, 2005, p. 19). "If it works, it is a great opportunity; if not, I'm not concerned," Elliott stated...
St. Jude Credits Soaring ICD Sales To Its Product Line, Not Guidant Recall
St. Jude Medical says it will continue marketing its products with the assumption that Guidant's resynchronization defibrillators (CRT-D) will return to the market by the end of the third quarter
Off-Label Photodynamic Therapy Coverage Extended To AMD Population
Clinical trial subgroup analyses showing the ability of lesion size to predict patient benefit helped convince CMS to expand national Medicare coverage of QLT/Novartis' Visudyne (verteporfin)